VRTX
Vertex Pharmaceuticals IncorporatedEvidence as of 2026-09-09The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on VRTX
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or olde…
Management team
- Dr. Ourania Tatsis Ph.D. · Executive VP and Chief Regulatory & Quality OfficerFind on LinkedIn
- Dr. David M. Altshuler M.D., Ph.D. · Executive VP & Chief Scientific OfficerFind on LinkedIn
- Mr. Stuart A. Arbuckle B.Sc. · Executive VP & COOFind on LinkedIn
- Mr. Charles F. Wagner Jr. · Executive VP & CFOFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.2 on a −2 to +2 scale (was −0.1 before the debate changed the read).
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The evidence balance is Mixed ( -0.2 of a possible +2; confidence high). Revenue in Q2 2026 (fiscal quarter ended 2026-07-31) was $ 3,333,900,000, up from $ 2,986,900,000 in Q1 2026 (fiscal quarter ended 2026-04-30) and from $ 2,964,700,000 in Q2 2025 (fiscal quarter ended 2025-07-31). Operating income in Q2 2026 was $ 1,246,900,000 and net income was $ 1,099,800,000, producing diluted EPS of $ 4.31 for the quarter; these figures are higher than the immediately preceding quarter and the year-earlier quarter.
The company shows shrinking share counts (weighted-average diluted shares down to 255,200,000 and common shares outstanding down to 253,460,924 as of 2026-07-31), a cash balance of $ 6,143,500,000 as of 2026-06-30, explicit Q1 2026 buyback cash outflows of $ 336,900,000, and trailing twelve‑month metrics that place price-to‑FCF at 32.38 and EV/EBITDA at 25.91.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Revenue was $3,333,900,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo), up from $2,986,900,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and up from $2,964,700,000 in fiscal Q2 2026 (2025-04-01 to 2025-06-30, 3mo).
XBRL companyfacts · 0000875320-26-000259Operating income was $1,246,900,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo), compared with $1,138,100,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and $1,151,100,000 in fiscal Q2 2026 (2025-04-01 to 2025-06-30, 3mo).
XBRL companyfacts · 0000875320-26-000259Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
In the Annual Report on Form 10‑K filed 13 February 2026, the company added and materially reworded risk language emphasizing that a concentrated source of revenue from its cystic fibrosis (CF) medicines increases risks if the company is unable to "sustain or increase revenues from sales of our CF medicines," including because of competitive products or failure to develop next‑generation medicines.
10-K filed 2026-02-13The 10‑K filed 13 February 2026 expanded risk disclosure about pricing and reimbursement pressures, calling out government and payer initiatives (including recent U.S. executive orders and rulemaking and August 2023 developments) and noting that such measures "could limit the prices of, or access to, our products" and could delay, deny, or otherwise adversely affect reimbursement.
10-K filed 2026-02-13Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
Momentum over the trailing 3 months is +19.4% (3-month momentum).
Moneyta signal set · 2026-09-08weakened in debateMomentum over the trailing 6 months is +14.8% and ranks in the 67th percentile of the 548-stock research universe.
Moneyta signal set · 2026-09-08weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
Institutional 13F filers reported a total VRTX position value of $102.65B as of the reported quarter ended 2026-03-31, with 1,689 holders and a quarter-over-quarter reported value change of -2.9%.
13F holdings · 1689 filers · as of 2026-03-31Top reported institutional holders in the 2026-03-31 13F data included Capital World Investors at $11.33B (value_qoq_pct -2.1), BlackRock, Inc. at $10.70B (value_qoq_pct -0.6), and Capital Research Global Investors at $9.43B (value_qoq_pct +20.2).
13F holdings · 1689 filers · as of 2026-03-31Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Goldman Sachs added Vertex Pharmaceuticals to its conviction list, a positive-themed headline carried by finance.yahoo.com on 2026-09-08.
News · finance.yahoo.com · 2026-09-08The same Goldman Sachs conviction-list headline about Vertex was also carried by fool.com on 2026-09-08, showing the story ran across multiple distinct outlets.
News · fool.com · 2026-09-08Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Carmen Bozic (EVP and CMO) recorded multiple sales under a stated 10b5-1 plan totaling the following reported transactions: $3.1M (6 May–12 May 2026, 6/12/2026 filing), $1.8M (15 Jun 2026), $888k (29 May 2026), $614k (15 May 2026), $785k (5 Jun 2026), $471k (18 Jun 2026), and $288k (26 Jun 2026).
Form 4 · Bozic Carmen (EVP and CMO) · $3.1M sold · 2026-05-12Joy Liu (EVP and Chief Legal Officer) reported a sale of "$364k" for 828 shares on 1 June 2026 that the filing states was executed under a 10b5-1 plan, and a separate sale of "$469k" for 1,104 shares reported on 1 May 2026 also stated as under a 10b5-1 plan.
Form 4 · Liu Joy (EVP and Chief Legal Officer) · $364k sold · 2026-06-01Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The price used in this analysis (528.9 on 2026-09-08) implies an FCF growth rate of 21.14% per year under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closeweakened in debateTrailing twelve‑month free cash flow is $4,168,900,000 and price-to‑FCF (TTM) is 32.38.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
The body of fundamentals evidence (fundamentals-0 through fundamentals-3, fundamentals-6) shows sequential revenue, operating income, net income, and diluted EPS expansion quarter-over-quarter, together with a rising cash balance — a coherent operating and liquidity signal that supports a favorable read. Share-count reductions and explicit buybacks (fundamentals-4, fundamentals-5, fundamentals-7) amplify per-share metrics and are consistent with capital-return activity; institutional holdings and recent sell-side conviction additions (ownership-0, ownership-1, news-0, news-1) provide market validation and positive momentum (market-0 through market-3) that complement the company-specific financials. The bear points based on the 10‑K risk expansions (filings-0 through filings-3) and headlineized insider sales are factual but represent disclosure and routine 10b5-1 activity; the company’s net-cash position (valuation-4) and meaningful trailing FCF (valuation-1) mitigate immediate balance-sheet concerns. Evidence strength: the operational figures and cash balances come from recent SEC filings (high strength), buyback and share-count measures are explicit (high strength), momentum and institutional holding signals are market-data based (moderate strength), while the expanded risk disclosures are high-quality but qualitative in nature (high strength) and insider plan sales are documented filings but consistent with planned-program disclosures (moderate strength).
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.35
46 surviving claims rest on 21 distinct sources; the heaviest analyst carries 22% of them, and 96% of what the desk raised survived the debate.
The surviving read is moderately robust: 46 claims draw from 21 distinct sources, so the evidence is not single-sourced but does lean on a few heavier contributors. One analyst accounts for about a fifth of the surviving claims and nearly all desk challenges (96%) persisted, which raises caution that debated counterpoints were largely not sustained; treat conclusions as informational and weight them with attention to those concentration risks.
Peer context · computed, not argued
12-1 momentum ranks 4th of 5 in Biotechnology (as of 2026-09-08).
6-month relative strength ranks 4th of 5 in Biotechnology (as of 2026-09-08).
90-day volatility ranks 5th of 5 in Biotechnology (as of 2026-09-08).
dividend yield ranks 3rd of 5 in Biotechnology (as of 2026-09-08).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
11 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer+0.9 to the score
10 documents· 4 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−0.7 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.4 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.5 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
18 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot+0.0 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on VRTX Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.